COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ICCVAM Logo

ICCVAM Biennial Report 2018-2019

ICCVAM Biennial Report 2018-2019
Menu
https://ntp.niehs.nih.gov/go/892766

Guidance on Reproductive Toxicity Testing and Labeling Recommendations for Oncology Pharmaceuticals

The FDA guidance document “Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations” was finalized in May 2019 and provides information for the development of pharmaceuticals that are intended to treat patients with cancer. The guidance notes that, in some cases, a weight-of-evidence approach showing potential for reproductive toxicity may eliminate the need to conduct a dedicated embryofetal development study. Such weight-of-evidence approaches can consider data from alternative assays, such as fit-for-purpose in vitro, ex vivo, or nonmammalian in vivo assays. The guidance also illustrates other cases where certain developmental and reproductive toxicity testing may not be warranted.

Tags: